<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268163</url>
  </required_header>
  <id_info>
    <org_study_id>DOE061</org_study_id>
    <nct_id>NCT01268163</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer</brief_title>
  <official_title>A Phase 1, Double-blinded, Randomised, Multi-centre, Three-period, Three-treatment, Crossover Study to Compare the Intravenous Pharmacokinetic and Safety Characteristics of European Taxotere® and American Taxotere® With Hospira Docetaxel Injection Administered at a Therapeutic Dose in Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetic and safety characteristics of&#xD;
      European Taxotere® and American Taxotere® with Hospira Docetaxel injection in patients with&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No information is available on the pharmacokinetic characteristics, safety or efficacy of&#xD;
      Hospira Docetaxel Injection. The primary purpose of this study therefore is to compare the&#xD;
      pharmacokinetic characteristics of 60-100 mg/m² Hospira Docetaxel Injection, 60-100 mg/m²&#xD;
      European Taxotere® (Taxotere® EU) and 60-100 mg/m² American Taxotere® (Taxotere® US) when&#xD;
      administered as a 1 hour intravenous infusion in man. The secondary objective of this study&#xD;
      will be to compare the safety and tolerability of Hospira Docetaxel Injection, Taxotere® EU&#xD;
      and Taxotere® US. The study will also provide an opportunity to assess selected efficacy&#xD;
      endpoints according to local practice after each cycle of treatment.&#xD;
&#xD;
      The study dosing regimen (60-100 mg/m², administered as a 1 hour intravenous infusion at 3&#xD;
      week intervals) and subject population (cancer patients for whom Taxotere® monotherapy would&#xD;
      be a suitable treatment option) were selected on the basis of the licensed use of 60-100&#xD;
      mg/m² Taxotere®. The randomised crossover design was chosen to reduce the effect of&#xD;
      intersubject variation.&#xD;
&#xD;
      Since Hospira Docetaxel Injection has not been administered to man there is no information on&#xD;
      the risks associated with its clinical use. However the active ingredient of Hospira&#xD;
      Docetaxel Injection is the same as that of Taxotere® and it is expected that Hospira&#xD;
      Docetaxel Injection will exhibit a similar safety and tolerability profile.&#xD;
&#xD;
      An estimated 24 patients will be recruited at several United Kingdom sites and one Russian&#xD;
      site to provide 19 evaluable patients&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration time curve from zero to last measured concentration (AUC[0-tlast])</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration observed (Cmax)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from zero to infinity (AUC0-∞)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half life (t1/2)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total plasma clearance (CL)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vss)</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve for unbound docetaxel</measure>
    <time_frame>On Day 1, 2, 3, 22, 23, 24, 43, 44, 45 (pre-dose and 30 min, 58 min, 65 min, 70 min, 90 min, 2 hr, 3 hr, 5 hr, 7 hr, 24±2 hr and 48±2 hr after starting Investigational medicinal product infusion during each treatment cycle).</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>European Taxotere® (Taxotere EU) 60-100 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hospira Docetaxel Injection 60-100 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>American Taxotere® (Taxotere US) 60-100 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>European Taxotere®</intervention_name>
    <description>60-100 mg/m^2 IV</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>American Taxotere®</intervention_name>
    <description>60-100 mg/m^2 IV</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hospira Docetaxel Injection</intervention_name>
    <description>60-100 mg/m^2 IV</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent given;&#xD;
&#xD;
          -  Have medically documented cancer for which Taxotere® monotherapy would be a suitable&#xD;
             treatment option;&#xD;
&#xD;
          -  Aged ≥18 years;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status between 0 - 1&#xD;
             (inclusive);&#xD;
&#xD;
          -  Haematological and serum chemical parameters that comply with the following criteria&#xD;
             (based on local laboratory normal reference range):&#xD;
&#xD;
               -  Haemoglobin ≥9.5 g/dL&#xD;
&#xD;
               -  Leukocytes ≥3.0 x 10^9/L&#xD;
&#xD;
               -  Neutrophils ≥1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥100 x 10^9 L&#xD;
&#xD;
               -  Total bilirubin ≤2.0 x Upper Limit of Normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤2.5 x ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) ≤2.5 x ULN&#xD;
&#xD;
               -  Alkaline phosphatase ≤4.0 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤1.5 x ULN&#xD;
&#xD;
          -  Willing to use an effective method of contraception, i.e. intrauterine device (IUD),&#xD;
             oral contraceptive, subdermal implant or double barrier (condom with a contraceptive&#xD;
             sponge or contraceptive suppository), unless anatomically sterile, from screening&#xD;
             until at least 12 weeks after last dose of Investigational Medicinal Product.&#xD;
&#xD;
          -  Willing and able to comply with the requirements of the protocol and available for the&#xD;
             planned duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant treatment with any other cytotoxic agent;&#xD;
&#xD;
          -  Concomitant use of compounds that induce, inhibit or are metabolized by cytochrome&#xD;
             P450, e.g. ciclosporin, ketoconazole, erythromycin, St John's Wort;&#xD;
&#xD;
          -  History or presence of any clinically significant findings that, in the opinion of the&#xD;
             Investigator, would preclude inclusion in the study;&#xD;
&#xD;
          -  Clinically significant vital signs or 12-lead electrocardiogram (ECG) results, as&#xD;
             judged by the Investigator;&#xD;
&#xD;
          -  Participation in any other clinical trial using an Investigational Medicinal Product&#xD;
             within the previous month&#xD;
&#xD;
          -  History of Hepatitis B Virus, Hepatitis C Virus or Human Immunodeficiency Virus;&#xD;
&#xD;
          -  Recent or clinically significant history of drug or alcohol abuse;&#xD;
&#xD;
          -  Insulin-dependent or unstable Diabetes Mellitus;&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to Taxotere® or to other drugs formulated&#xD;
             with Polysorbate 80;&#xD;
&#xD;
          -  History of reaction to any drug containing polyethylene glycol 300 (PEG 300);&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Ranson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christie Hospital, Manchester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V Semiglazov</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Petrov Research Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Docetaxel</keyword>
  <keyword>Phase I</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

